141(top 1%)
papers
7.7K(top 1%)
citations
42(top 1%)
h-index
87(top 1%)
g-index
157
all documents
8.9K
doc citations
1.3K
citing journals

Top Articles

#TitleJournalYearCitations
168Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerJournal of Nuclear Medicine2019874
2Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung CancerJournal of Clinical Oncology2020710
3Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialLancet Respiratory Medicine,the2019704
4First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersJournal of Clinical Oncology2019457
5Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology2022445
6Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2019418
7Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respiratory Medicine,the2016349
8Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC TrialJournal of Thoracic Oncology2021323
9Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189Annals of Oncology2021213
10IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCJournal of Thoracic Oncology2021212
11Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine2017169
12Old ideas to innovate tuberculosis control: preventive treatment to achieve eliminationEuropean Respiratory Journal2013163
13Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyJournal of Clinical Oncology2021146
14Targeting KRAS in non-small-cell lung cancer: recent progress and new approachesAnnals of Oncology2021134
15Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncology, The2020119
16IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainJournal of Thoracic Oncology2022114
17Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung CancerJAMA Oncology2021113
18Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPDRespiratory Medicine2015108
19Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung CancerJAMA Oncology2021105
20Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary DiseaseChest2018102
21Clinicopathologic Features of Advanced Squamous NSCLCJournal of Thoracic Oncology2016101
22Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled StudyAmerican Journal of Respiratory and Critical Care Medicine201996
23ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerESMO Open202096
24Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysisThorax201988
25Challenges in lung cancer therapy during the COVID-19 pandemicLancet Respiratory Medicine,the202088
26Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)European Journal of Cancer202086
27Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT studyAnnals of Oncology201376
28Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyJournal of Clinical Oncology202375
29Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del allelesERJ Open Research201972
30Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group surveyEuropean Journal of Cancer201869
31Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized TrialsAmerican Journal of Respiratory and Critical Care Medicine201860
32Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionThorax201859
33ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPDInternational Journal of COPD201753
34Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Lung Cancer202153
35Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialLancet Respiratory Medicine,the202253
36Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutationsExpert Review of Respiratory Medicine202051
37KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLCAnnals of Oncology201950
38Small cell lung cancer: a slightly less orphan disease after immunotherapyAnnals of Oncology202149
39Changes in IgE sensitization and total IgE levels over 20 years of follow-upJournal of Allergy and Clinical Immunology201648
40Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthmaPulmonary Pharmacology and Therapeutics201747
41Noninvasive Analysis of Microbiome Dynamics in the Fruit Fly Drosophila melanogasterApplied and Environmental Microbiology201346
42The H2S-generating enzymes cystathionine β-synthase and cystathionine γ-lyase play a role in vascular development during normal lung alveolarizationAmerican Journal of Physiology - Lung Cellular and Molecular Physiology201546
43Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary DiseaseFrontiers in Physiology201746
44Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial202245
45Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 TrialJournal of Thoracic Oncology202243
46KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.Journal of Clinical Oncology201942
47Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.Journal of Clinical Oncology202042
48Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyLung Cancer201641
49Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung CancerJournal of Thoracic Oncology201941
50Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPDPulmonary Pharmacology and Therapeutics201340